Lilly/BI Gain Japan Approval For First Lantus Biosimilar
This article was originally published in PharmAsia News
Lilly and Boehringer Ingelheim have confirmed that they have received regulatory approval in Japan for their insulin glargine product as the first biosimilar version of Sanofi's Lantus, the first such local competition for the branded basal insulin analog.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, world-first nods for the country’s second HIF-PH inhibitor and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.